Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 1/2024

05-06-2023 | Acute Myeloid Leukemia | ORIGINAL ARTICLE

Lower Levels of TET2 Gene Expression, with a Higher Level of TET2 Promoter Methylation in Patients with AML; Evidence for the Role of Aberrant Methylation in AML Pathogenesis

Authors: Bahare Ghasemi, Javad Ahmadi, Farhad Zaker, Tahere Tabatabaei, Masoumeh Kiani-Zadeh, Ahmad Kazemi

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2024

Login to get access

Abstract

DNA methylation is a key epigenetic mechanism that is dysregulated in leukemia and plays a significant role in leukemogenesis. Ten-eleven translocation 2 (TET2) is one of the most frequently mutated genes among the DNA methylation regulators in hematologic malignancies, indicating its tumor-suppressor function. In this study, we investigated the expression and methylation status of TET2 in patients with AML. Quantitative RT-PCR was used to evaluate TET2 expression in peripheral blood mononuclear cells (PBMCs) from 51 newly diagnosed AML patients and 50 healthy controls. The methylation-sensitive high-resolution melting (MS-HRM) method was used in 45 patients with AML and 15 healthy controls to evaluate the promoter methylation of TET2. TET2 expression was significantly downregulated (P < 0.0001) in patients with AML compared to that in healthy controls. Furthermore, the methylation level of the TET2 promoter was significantly different between patients and controls. Aberrant methylation of the TET2 promoter was observed in 53.3% of the patients. Interestingly, a negative (− 0.3138) and significant (P = 0.0358) correlation between TET2 methylation and expression was found. The survival of patients with downregulated TET2 was poorer than that of other patients. TET2 gene expression was significantly downregulated while the promoter methylation was higher in patients, indicating that TET2 may be a tumor suppressor gene and a prognostic factor in AML and that transcriptional silencing of the TET2 gene may play a role in AML pathogenesis. Since epigenetic mechanisms are reversible, abnormal TET2 methylation could become a therapeutic target in the future.
Literature
1.
O’Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E et al (2012) Acute myeloid leukemia. J Natl Compr Canc Netw 10(8):984–1021CrossRefPubMed
2.
O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA et al (2017) Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15(7):926–957CrossRefPubMed
3.
Ohgami R, Arber D (2015) The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia. Int J Lab Hematol 37:122–132CrossRefPubMed
4.
Lim SH, Dubielecka PM, Raghunathan VM (2017) Molecular targeting in acute myeloid leukemia. J Transl Med 15(1):1–13CrossRef
5.
Wouters BJ, Delwel R (2016) Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood J Am Soc Hematol 127(1):42–52
6.
7.
Eriksson A, Lennartsson A, Lehmann S (2015) Epigenetic aberrations in acute myeloid leukemia: early key events during leukemogenesis. Exp Hematol 43(8):609–624CrossRefPubMed
8.
Hale V, Hale GA, Brown PA, Amankwah EK (2017) A review of DNA methylation and microRNA expression in recurrent pediatric acute leukemia. Oncology 92(2):61–67CrossRefPubMed
9.
Zhang Y, Jiang Q, Kong X, Yang L, Hu W, Lv C et al (2016) Methylation status of the promoter region of the human frizzled 9 genes in acute myeloid leukemia. Mol Med Rep 14(2):1339–1344CrossRefPubMed
10.
11.
Langemeijer S, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41(7):838–842CrossRefPubMed
12.
Chim C, Wan T, Fung T, Wong K (2010) Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms. J Clin Pathol 63(10):942–946CrossRefPubMed
13.
14.
Van Damme M, Crompot E, Meuleman N, Maerevoet M, Mineur P, Bron D et al (2016) Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance. Clin Epigenetics 8(1):1–11
15.
16.
17.
Duployez N, Goursaud L, Fenwarth L, Bories C, Marceau-Renaut A, Boyer T et al (2020) Familial myeloid malignancies with germline TET2 mutation. Leukemia 34(5):1450–1453CrossRefPubMed
18.
Woods BA, Levine RL (2015) The role of mutations in epigenetic regulators in myeloid malignancies. Immunol Rev 263(1):22–35CrossRefPubMed
19.
20.
Solary E, Bernard O, Tefferi A, Fuks F, Vainchenker W (2014) The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 28(3):485–496CrossRefPubMed
21.
22.
Langemeijer SM, Aslanyan MG, Jansen JH (2009) TET proteins in malignant hematopoiesis. Cell Cycle 8(24):4044–4048CrossRefPubMed
23.
Kim Y-H, Pierscianek D, Mittelbronn M, Vital A, Mariani L, Hasselblatt M et al (2011) TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol 64(10):850–852CrossRefPubMed
24.
Wojdacz TK, Dobrovic A, Hansen LL (2008) Methylation-sensitive high-resolution melting. Nat Protoc 3(12):1903–1908CrossRefPubMed
25.
Coutinho DF, Monte-Mór BC, Vianna DT, Rouxinol ST, Batalha ABW, Bueno APS et al (2015) TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood. Leuk Res 39(10):1103–1108CrossRefPubMed
26.
27.
28.
Yao H, Duan M, Lin L, Wu C, Fu X, Wang H et al (2017) TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population. Oncotarget 8(11):18337CrossRefPubMedPubMedCentral
29.
Yang J, Xiao X, Li R, Li Z, Deng M, Zhang G (2016) Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia. Cancer Biomark 16(1):81–88CrossRefPubMed
30.
31.
Kroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T et al (2014) Characterization of acute myeloid leukemia based on levels of global hydroxymethylation. Blood J Am Soc Hematol 124(7):1110–1118
32.
33.
Kunimoto H, Nakajima H (2021) TET2: A cornerstone in normal and malignant hematopoiesis. Cancer Sci 112(1):31–40CrossRefPubMed
34.
35.
Scopim-Ribeiro R, Machado-Neto JA, de Melo CP, Niemann FS, Lorand-Metze I, Costa FF et al (2016) Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. Diagn Pathol 11(1):1–5CrossRef
36.
Hamed NA, El Halawani NA, Kassem HS, Ayad MW, Dammag EA (2015) TET2 expression in a cohort of Egyptian acute myeloid leukemia patients. Egypt J Haematol 40(4):159CrossRef
37.
Zhang TJ, Zhou JD, Yang DQ, Wang YX, Wen XM, Guo H et al (2018) TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia. J Cell Physiol 233(8):5838–5846CrossRefPubMed
38.
Pierscianek D, Teuber-Hanselmann S, Ahmadipour Y, DarkwahOppong M, Unteroberdörster M, Müller O et al (2020) TET2 promotor methylation and TET2 protein expression in pediatric posterior fossa ependymoma. Neuropathology 40(2):138–143CrossRefPubMed
39.
Barazeghi E, Gill AJ, Sidhu S, Norlén O, Dina R, Palazzo FF et al (2017) A role for TET2 in parathyroid carcinoma. Endocr Relat Canc 24(7):329–338CrossRef
40.
41.
Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM et al (2013) The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 13(1):87–101CrossRefPubMedPubMedCentral
42.
Wang J, He N, Wang R, Tian T, Han F, Zhong C et al (2020) Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia. Sci Rep 10(1):1–11
43.
Bahari G, Hashemi M, Naderi M, Taheri M (2016) TET2 promoter DNA methylation and expression in childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev 17(8):3959–3962PubMed
44.
Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J et al (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood J Am Soc Hematol 113(25):6403–6410
Metadata
Title
Lower Levels of TET2 Gene Expression, with a Higher Level of TET2 Promoter Methylation in Patients with AML; Evidence for the Role of Aberrant Methylation in AML Pathogenesis
Authors
Bahare Ghasemi
Javad Ahmadi
Farhad Zaker
Tahere Tabatabaei
Masoumeh Kiani-Zadeh
Ahmad Kazemi
Publication date
05-06-2023
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2024
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-023-01673-y

Other articles of this Issue 1/2024

Indian Journal of Hematology and Blood Transfusion 1/2024 Go to the issue

ORIGINAL ARTICLE

Short-Term Impact of Hematopoietic Stem Cell Transplantation on Depressive Behavior, Cognition and Quality of Life in Leukemia Patients

Original Article

Metformin as a Fetal Hemoglobin Inducer in Non-transfusion Dependent Thalassemia Patients

ORIGINAL ARTICLE

Potential Clinical Role of LncRNA miR503HG in Multiple Myeloma and its Effect on the Proliferation and Adhesion of Myeloma Cells

REVIEW ARTICLE

Analytical Appraisal of Hematogones in B-ALL MRD Assessment Using Multidimensional Dot-Plots by Multiparametric Flow Cytometry: A Critical Review and Update

ORIGINAL ARTICLE

COVID-19 Vaccine Uptake in Patients with Multiple Myeloma and AL Amyloidosis: A Cross-Sectional Observational Study from India

IMAGES

Germline CSF3R, RUNX1 and ETV6 Pathogenic Variants in a Case of Atypical Chronic Myeloid Leukemia: Individual to Familial Unravelling by Next Generation Sequencing
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits